Want to see GB:HEMO full AI Analyst Report?
HemoGenyx Pharmaceuticals Plc (HEMO) Ratios
HemoGenyx Pharmaceuticals Plc Ratios
GB:HEMO's free cash flow for Q2 2026 was $-1.66M. For the 2026 fiscal year, GB:HEMO's free cash flow was increased by $0.00 and operating cash flow was $-1.66M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.38 | 0.72 | 3.33 | 3.47 | 20.23 |
| Quick Ratio | 1.38 | 0.72 | 3.33 | 3.47 | 20.23 |
| Cash Ratio | 1.08 | 0.14 | 1.91 | 3.38 | 19.39 |
| Solvency Ratio | -3.03 | -1.48 | -1.82 | -0.89 | -14.09 |
| Operating Cash Flow Ratio | -2.35 | -3.55 | -9.36 | -3.89 | -7.45 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -9.72 | -22.36 | -9.03 | -258.80 |
| Net Current Asset Value | $ -996.96K | $ -2.52M | $ -1.16M | $ -1.25M | $ 6.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.48 | 0.62 | 0.48 | 0.48 | 0.00 |
| Debt-to-Equity Ratio | 1.68 | 2.92 | 1.05 | 1.05 | 0.00 |
| Debt-to-Capital Ratio | 0.63 | 0.75 | 0.51 | 0.51 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.49 | 4.69 | 2.17 | 2.17 | 1.04 |
| Debt Service Coverage Ratio | -17.74 | -6.78 | -9.74 | -11.74 | -1.84 |
| Interest Coverage Ratio | -20.30 | -21.09 | -17.59 | 121137.82 | -1.04 |
| Debt to Market Cap | 0.00 | 0.03 | 0.01 | 0.02 | 0.00 |
| Interest Debt Per Share | 0.50 | 0.88 | 1.16 | 1.40 | 1.35 |
| Net Debt to EBITDA | -0.10 | -0.52 | -0.30 | -0.26 | 2.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.93% | 99.89% | 99.91% | 99.81% | 99.82% |
| EBT Per EBIT | 209.56% | 98.23% | 120.47% | -99.74% | 189.00% |
| Return on Assets (ROA) | -233.73% | -133.42% | -109.58% | -56.11% | -59.85% |
| Return on Equity (ROE) | -816.50% | -626.08% | -237.37% | -121.49% | -62.25% |
| Return on Capital Employed (ROCE) | -172.22% | -187.58% | -101.92% | 63.01% | -33.09% |
| Return on Invested Capital (ROIC) | -148.02% | -146.83% | -92.64% | 57.20% | -33.01% |
| Return on Tangible Assets | -244.38% | -150.48% | -118.72% | -59.83% | -63.12% |
| Earnings Yield | -38.41% | -42.03% | -25.76% | -30.54% | -35.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.61 | 0.94 | 2.14 | 6.94 | 0.96 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -598.35 | -390.12 | -170.55 | -52.56 | -380.68 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 598.35 | 390.12 | 170.55 | 52.56 | 380.68 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.78 | -1.25 | -2.16 | -1.19 | -1.36 |
| Free Cash Flow Per Share | -0.78 | -1.25 | -2.20 | -1.36 | -1.78 |
| Dividend Paid and CapEx Coverage Ratio | -879.37 | -309.91 | -52.06 | -6.79 | -3.21 |
| Capital Expenditure Coverage Ratio | -879.37 | -309.91 | -52.06 | -6.79 | -3.21 |
| Operating Cash Flow Coverage Ratio | -1.72 | -1.57 | -2.07 | -0.85 | -258.80 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.58% | -30.89% | -23.96% | -25.63% | -23.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.60 | -2.38 | -3.88 | -3.27 | -2.85 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 21.26 | 14.90 | 9.21 | 3.98 | 1.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.36 | -3.24 | -4.17 | -3.90 | -4.22 |
| Price-to-Operating Cash Flow Ratio | -7.37 | -3.25 | -4.25 | -4.48 | -5.54 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | 0.08 | -0.08 | 0.08 | -0.09 |
| Enterprise Value Multiple | -6.34 | -3.36 | -4.82 | -4.07 | -3.23 |
| Enterprise Value | 25.83M | 15.83M | 27.67M | 13.92M | 7.72M |
| EV to EBITDA | -6.34 | -3.36 | -4.82 | -4.07 | -3.23 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.48 | -3.83 | -4.45 | -4.17 | -2.24 |
| EV to Operating Cash Flow | -7.49 | -3.85 | -4.53 | -4.78 | -2.94 |
| Tangible Book Value Per Share | 0.22 | 0.11 | 0.82 | 1.14 | 3.99 |
| Shareholders’ Equity Per Share | 0.27 | 0.27 | 1.00 | 1.34 | 4.23 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.09 | -0.47 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.20 | -1.70 | -2.37 | -1.62 | -2.64 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.10 | 1.05 | 1.05 | 1.00 | 2.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.35 | 0.73 | 0.91 | 0.73 | 0.51 |
Currency in GBP
